Sengenics Announces Commercial Partnership with RayBiotech for its Immunome Protein Array Technology

Share on facebook
Share on whatsapp
Share on twitter
Share on linkedin

Sengenics, a genomics and proteomics-based research and diagnostics services company and Raybiotech, a leading USA-based global provider of ELISA and multiplex protein detection technologies, today announced that they have entered into a commercial partnership to co-brand Sengenics™ flagship protein array platform, Immunome™.


Sengenics Commercial Director, Matthew Rawlings, said, “The Raybiotech-Sengenics relationship is a very exciting commercial development to enhance Immunome™’s overall market potential. Sengenics will leverage Raybiotech’s worldwide commercial expertise in proteomics with the unique features of the Immunome™ protein array, namely, the world’s only protein array platform with 100% correctly folded, full-length and functionally validated proteins. Our aim working together will be to provide mutual customers the ability to use this technology for a wide variety of proteomics applications including autoimmune and cancer biomarker discovery; measuring and monitoring global immune response to drugs; as well as carrying out on-array kinase inhibitor drug assays.”


Raybiotech currently has over 60 distributors in more than 40 countries globally, and has established a very strong presence in the United States, Europe and China. As part of the partnership, Sengenics and Raybiotech will focus on dual-branding, marketing and distribution strategies for Immunome™ protein arrays and associated services.


A fundamental differentiating factor of Immunome™ protein arrays is that proteins are never allowed to dry out, ensuring that they maintain the correct conformation and hence remain functional. For this reason Immunome™ protein arrays are shipped on dry ice from multiple global locations. To simplify shipping logistics, Sengenics and Raybiotech will hold stock of Immunome™ protein arrays in five locations: Arizona and Georgia, Guangzhou, Brunei and Singapore.


About Sengenics


Sengenics is a genomics and proteomics-based research and diagnostics company, with a range of patented technologies and products that are marketed to pharmaceutical companies, scientists and hospitals. Its flagship technology is the patented Immunome™ auto-antibody profiling platform which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge in 1996. It also has additional patented and proprietary products for Human diseases that use the ThalaSURE™ and Genoverse™ brand names.



Related news link:

Sign up for our Newsletter

Insert your email to sign up to our newsletter.


Resources to access our technology


Your technical questions - answered


One technology - endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

© 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361